Zydus Lifesciences Ltd (CADILAHC) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally.

Total Assets Chart for Zydus Lifesciences Ltd

Zydus Lifesciences Ltd (CADILAHC) total assets for FY2021 were INR 238.8B, a 0.8% change from FY2020. Zydus Lifesciences Ltd's total assets grew from INR 13.4B in 2004 to INR 238.8B in 2021 (1679.4% over 17 years). Total assets compound annual growth rate: 5-year CAGR of 19.0%, 10-year CAGR of 18.0%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (Indian Rupees)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
₹354.27B
Implied Share Price
₹346.05
Enterprise Value
₹367.06B
Revenue (TTM)
₹157.61B
EBITDA
₹33.88B
Profit Margin
30.26%
Trailing P/E
7.43
Forward P/E
20.20
Price/Book (MRQ)
2.25
Price/Sales (TTM)
2.25
EV/EBITDA
10.64
EV/Revenue
2.39
Dividend Yield
0.00%
Book Value
₹158.15
Free Cash Flow (FY2021)
₹24.39B
Free Cash Flow Yield
6.88%

Snapshot as of 5th September 2023 — not point-in-time controlled, may lag the live market by a few days.